INTRODUCTION
Throughout 2020, the COVID-19 pandemic constituted a major challenge for medicine,
both for diagnosing and treating patients affected by SARSCoV-2. Clinical experience
gained during this period and the follow-up of infected patients in studies carried
out in the US, France and China showed that some patients considered recovered, either
according to clinical or laboratory factors, maintained the symptoms of COVID-19 even
after the acute phase of the disease1. The persistence of clinical signs in patients who have overcome the acute phase
of the virus infection led to the emergence of a new concept: the post-COVID syndrome,
a term that defines the maintenance of the symptoms of the disease after at least
6 months of recovery from its acute phase2.
Most centers specializing in the treatment of COVID-19 use two tests of Reverse Transcription
followed by Polymerase Chain Reaction (RT-PCR) consecutive negative, with upper respiratory
tract samples collected at 24-hour intervals, to define the criteria for patient discharge
or recovery. However, the emergence of the concept of post-COVID syndrome indicates
that the negative result of RT-PCR isolated no longer represents the guaranteed cure
of the patient but the beginning of a process of monitoring the same to control possible
manifestations of the disease.
Since microbiological tests’ negative results cannot define the full recovery of symptoms,
a big question arises: what is the safety of electively operating on a patient who
has already had COVID-19? Therefore, to minimize the postoperative risk, it is essential
to know the symptoms that may remain in the long term and their possible complications.
CASE REPORT
A 36-year-old female patient, previously healthy, started on December 11, 2020, with
fever, dry cough and diffuse myalgia. On December 18, through the RTPCR exam, she
confirmed the diagnosis of COVID-19. She was accompanied by a clinical doctor during
this period and showed remission of all symptoms, still at the end of December 2020,
without the need for hospital admission. She underwent a new RT-PCR test for SARS-CoV-2
on January 8, 2021, with a negative result. At that time, the patient was asymptomatic,
and after reassessment by the clinical assistant, she was released for surgical procedure
as she recovered from COVID-19.
The patient underwent a reduction mammoplasty procedure at Hospital da Plástica do
Rio de Janeiro, on January 14, 2021, under general anesthesia, with a total duration
of 5 hours, without complications. Liacyr Ribeiro’s type I pedicle technique was used
(Figure 1)3, with the ascent of the nipple-areolar complex (NAC) through the Letterman maneuver4.
Figure 1 - Liacyr Ribeiro technique.
Figure 1 - Liacyr Ribeiro technique.
On the first postoperative day, the patient had a dry cough and runny nose, symptoms
that had not been reported in the preoperative period, and asymmetric swelling between
the breasts, larger on the right, without signs of bleeding on examination. In addition,
she had a more pale right NAC when compared to the contralateral breast (Figure 2A). As measures to improve local vascularization and reduce edema, treatment was started
with: (1) 1ml of intramuscular betamethasone, single-dose, (2) 400mg of pentoxifylline
and (3) 50mg of cilostazol. On the same day, the patient was discharged from the hospital
with instructions to maintain the use, at home, of (1) antibiotic therapy with 875+125mg
of amoxicillin + potassium clavulanate, (2) staggered analgesia with 1g of dipyrone
and 10mg of trometamol ketorolac, (3) 400mg of pentoxifylline and 50mg of cilostazol
and (4) vitamin C, in a daily dose of 500mg.
Figure 2 - A: Right NAC on the 1st POD. B: Right NAC on the 3rd POD. C: Right NAC on the 5th POD. D: Right NAC on the 21st POD. NAC: Nipple-areolar complex; POD: Postoperative day.
Figure 2 - A: Right NAC on the 1st POD. B: Right NAC on the 3rd POD. C: Right NAC on the 5th POD. D: Right NAC on the 21st POD. NAC: Nipple-areolar complex; POD: Postoperative day.
On the third postoperative day, still with a persistent dry cough, the patient had
a darkened region on the lateral half of the right NAC, with involvement of the papilla
(Figure 2B). At that moment, 100mg of acetylsalicylic acid was added to the treatment once a
day to potentiate the antiplatelet action. On the fifth postoperative day, a new dose
of 1 ml of intramuscular betamethasone was administered since the right breast showed
only partial improvement in edema (Figure 2C).
Despite the complete improvement of the edema in the right breast and the efforts
of the assistant team to improve the vascularization of the right NAC, on the 21st
postoperative day, the patient presented superficial necrosis of the lateral half
of the right areola without compromising the papilla (Figure 2D). At that moment, alternate treatment was started with: (1) hydrogel ointment with
alginate and (2) collagenase ointment with topical chloramphenicol, aiming, respectively,
for hydration and superficial debridement of the fibrin area.
On the 26th postoperative day, the patient returned for an outpatient consultation, presenting
an area of f ibrin delimited in the right NAC. Mechanical debridement was performed
in the region of partial necrosis of the right areola, with subsequent primary suture
with complete wound closure. At that moment, she clinically presented with cough,
myalgia, and diffuse pain in the lower limbs, but without signs of deep thrombosis.
Palpation of peripheral arterial pulses in the lower limbs was performed, pain on
palpation of the calf when compressed towards the tibia, mobility of the calf compared
to the contralateral calf and Homans sign5 were evaluated, all negative. As a result of the progression of symptoms, the patient
was referred again to a clinician for follow-up.
On the return for the removal of stitches, on the 33rd postoperative day, the wound presented complete closure. It should be noted that
treatment with a skin graft was offered in the region of areolar necrosis; however,
the patient was satisfied with the final result (Figure 3) and chose only to complement the diameter of the areola with a tattoo.
Figure 3 - Final appearance of the right areola on the 33rd POD. POD: Postoperative day.
Figure 3 - Final appearance of the right areola on the 33rd POD. POD: Postoperative day.
In a late consultation, on the 69th postoperative day, the patient returned to the outpatient clinic without any surgical
complaints, however, she maintained a clinical picture of fatigue, myalgia in the
lower limbs and episodes of dry cough. When asked about the continuation of the cough,
she informed that she was followed up with a medical doctor and, despite the regular
use of antihistamine medication, she did not show improvement. Therefore, she was
guided through a medical report sent by the surgical team to the clinical assistant,
who investigated changes in the lung parenchyma with chest computed tomography.
Clinical and surgical follow-up should be maintained for at least 12 months to assess
the progression of clinical symptoms and the evolution of postoperative healing.
DISCUSSION
In fact, one of the possible unfavorable results related to the reduction mammaplasty
surgery is the NAC ischemic complication, a condition that was evidenced in the immediate
postoperative period of the reported case, with subsequent evolution to partial areola
necrosis. The incidence of areola necrosis in mammoplasty is variable in the literature.
Pinsolle et al.6 determined an incidence between 0.6 and 3.7% of this phenomenon in a review article.
In 1966, Mandrekas et al.7 described an incidence of 0.8% of NAC necrosis when using the inferior pedicle technique,
as performed in the report. Van Deventer et al.8 also defined the causes of NAC ischemia and necrosis as insufficient arterial supply
or venous congestion, the latter being the main cause8. Thus, NAC necrosis can be an infrequent complication but is expected from the surgical
procedure performed.
In addition to areola necrosis, another point that draws attention in the patient’s
history is respiratory symptoms, correlated with a probable post-COVID syndrome. This
condition is defined as the persistence of one or more symptoms of COVID-19, or symptoms
related to the disease, for at least 6 months in patients who have recovered from
the acute phase of the infection2. In patients who present this condition with an evolution period of fewer than six
months, the diagnosis of Post-Infectious Fatigue Syndrome is correct2.
Lamprecht2 cites that, after infection with SARSCoV-2, 35% of outpatients and 87% of hospitalized
patients are affected by the post-COVID syndrome or the Infectious Fatigue syndrome,
depending on the analyzed population. Similarly, it is interesting to note that several
patients developed persistent symptoms after the acute episode of infection during
the SARS-CoV-1 (Severe Respiratory Distress syndrome) epidemic in 20039, especially healthcare workers. These symptoms were characterized as a syndrome of
Chronic Fatigue or myalgic encephalomyelitis10, and a relationship between the maintenance of these symptoms and the development
of psychological diseases was evidenced. Moderate to severe depression and anxiety
were described in more than one-third of patients after one year of recovery from
the initial condition11.
In patients affected by post-COVID-19 syndrome, fatigue was reported as the most important
persistent symptom2,12. Its causative mechanism is still not entirely clear, but the cause is estimated
to be multifactorial. In a study conducted in Egypt in 2020, Kamal et al.13 evaluated 287 patients described as survivors of the disease and of these, only 10.8%
had no symptoms after recovery from the acute phase. The persistence of symptoms in
the study was defined as their maintenance for at least 20 days from the last negative
PCR test. A wide variety of post-COVID symptoms have been described, from mild symptoms
such as persistent headache (28.9%) to severe conditions such as acute myocardial
infarction, renal failure, and pulmonary fibrosis. It is worth mentioning that, among
the patients who maintained the symptoms, 72.8% had persistent fatigue, 38% had anxiety,
and 31.4% had joint pain13.
Psychological manifestations, as previously described in SARS-CoV-1 infection, permanent
fibrotic changes in the lung parenchyma, and thromboembolic complications are also
noteworthy. Kamal et al.13 also point to a possible relationship between the severity of post-COVID-19 symptoms
and the initial condition of the disease; that is, the most severe cases of the initial
disease had the most severe post-COVID manifestations. Galván-Tejada et al.1, in parallel, in a case-control study carried out in the city of Zacatecas, Mexico,
in which they evaluated 219 patients, described dyspnea as the most important symptom
to suspect post-COVID syndrome since it was absent in the control group of 78 patients.
The pathophysiology of the post-COVID syndrome not yet elucidated generates suspicion
about its existence and questions about the possibility that the symptoms are the
result of a reinfection framework. Among those who defend its existence, Afrin et
al.14 propose that a possible basis for the post-COVID syndrome is the Mast Cell Activation
Syndrome (MAS). MAS is a chronic multisystem disorder with an estimated prevalence
of 17%, which is very similar to the number of COVID-19 cases that develop severe
forms of the disease, between 15 and 20%. A hyperinflammatory pattern is observed
in these patients, which progresses with an inflammatory cytokine storm characterized
by the rapid proliferation of T lymphocytes, macrophages, and NK cells. Without leukocyte
cytotoxic activity, this pattern causes cell death by activating the humoral immune
system.
In inflammation, mast cells play a central role since they are responsible for synthesizing
cytokines that mediate the intense immune response and regulate the activity of other
cell types involved in the process14. It should be noted that a significant number of fatal cases of COVID-19 are related
to cardiovascular complications, such as thromboembolism, pulmonary embolism and sepsis14, conditions whose pathophysiology involves mast cell activity.
Because of the above report, there is a correlation between the respiratory condition
and previous infection by COVID-19 since these symptoms are not expected after an
elective reduction mammoplasty surgery, especially in a previously healthy patient.
As already pointed out, the pathophysiological mechanisms responsible for the manifestation
of COVID-19 and the post-COVID syndrome are still uncertain; however, in the case
mentioned above, the chronological proximity between the SARS-CoV-2 infection and
the return of symptoms in the immediate postoperative period.
It is extremely important to emphasize that the clinical manifestations presented
by the patient are considered mild and that the differential diagnosis of the condition
could easily be achieved with the performance of complementary tests, such as imaging
and laboratory tests. However, as demonstrated, there are serious outcomes reported
in post-COVID syndrome, and the possibility of these conditions developing during
a postoperative period represents, in practice, a diagnostic and therapeutic challenge.
Although they are not considered classic postoperative symptoms, especially in cosmetic
surgery, cough and myalgia in the lower limbs should be promptly investigated, as
they are possible presentations in cases of pulmonary thromboembolism and deep vein
thrombosis. The presentation of deep vein thrombosis varies from the absence of symptoms
to the classic presence of swelling, pain, heat, and redness in the affected extremity.
Pulmonary thromboembolism, however, presents dyspnea, tachypnea, chest pain, syncope,
and cough as the main symptoms15.
Hatef et al.16 showed an estimated risk of venous thromboembolism of 2.91% in patients undergoing
aesthetic breast and upper extremity body contouring procedures, as reported in the
case reported. Tummy tuck and circumferential tummy tuck procedures are still associated
with higher risks of thromboembolism.
A wide variety of clinical and surgical complications may arise in the postoperative
period, which correlates with the surgical procedure performed and the patient’s clinical
factors. In times of a pandemic, a wide range of clinical presentations is added to
this scenario, from mild symptoms to severe outcomes, presented by patients with previous
infections by COVID-19. In this context, the question arises: could the clinical changes
presented by the patient, that is, the post-COVID syndrome, increase her risk of postoperative
complications? Also, to what extent could the endocrine-metabolic changes expected
in the postoperative period contribute to worsening the symptoms resulting from the
post-COVID syndrome?
Despite the lack of answers to most of these questions, the authors suggest that all
patients who will undergo elective surgery - aesthetic or otherwise -once previously
infected with SARS-CoV-2 be carefully evaluated for the presence of respiratory symptoms
and systemic in the preoperative period. The presence of symptoms must be reported
in the medical record and the decision to proceed with surgery, if symptoms arise
in the preoperative period, is an individual decision of each surgeon.
The American Society of Anesthesiology (ASA)17, in a statement issued on December 8, 2020, suggests different periods between surgery
and the initial picture of COVID-19 infection according to the severity of the condition
presented and the patient’s comorbidities. The ASA also cites the possibility of residual
conditions and long-term deleterious effects, both in the anatomy and myocardial function.
It is worth mentioning that the post-COVID syndrome is an entity still poorly understood,
with a wide range of clinical presentations, from mild symptoms to severe complications,
and, due to the inherent risks of surgical procedures, we believe that such a decision
should always be directed to ensure safety. of the patient, especially in elective
surgeries.
CONCLUSION
Post-COVID syndrome has a recent description and still requires more robust scientific
evidence to explain its pathophysiology. However, it is a fundamental clinical aspect
to be analyzed in the preoperative period of patients undergoing elective procedures.
As in the case reported, negative RT-PCR is not a complete guarantee of cured COVID-19
and, for this reason, a thorough clinical investigation is necessary to ensure that
the history of infection by the new coronavirus is not overlooked before surgery.
Therefore, it is concluded, because of the overall clinical presentation of the post-COVID
syndrome, which ranges from mild symptoms to severe complications, that the additional
risk of unfavorable outcomes should be evaluated in the postoperative period of patients
previously infected with COVID-19.
REFERENCES
1. Galván-Tejada CE, Herrera-García CF, Godina-González S, Villagrana-Bañuelos KE, Amaro
JDL, Herrera-García K, et al. Persistence of COVID-19 Symptoms after Recovery in Mexican
Population. Int J Environ Res Public Health. 2020;17(24):9367.
2. Lamprecht B. Gibt es ein Post-COVID-Syndrom? [Is there a postCOVID syndrome?]. Pneumologe
(Berl). 2020;17(6):398-405. German.
3. Gasperin BDM, Pavelecini M, Possamai LM, Freitas Neto FM de, Ely PB. Viabilidade do
uso de retalhos de Liacyr dos tipos I e III em mastopexias com implantes em pacientes
com incisão prévia no sulco inframamário. Rev Bras Cir Plást. 2018;33(Suppl.1):28-30.
4. Letterman G, Schurter M. Facilitation of the upward advancement of the nipple-areola
complex in reduction mammaplasty by Kiel resection. Plast Reconstr Surg. 1981;67(6):793-5.
5. Sternbach G. John Homans: the dorsiflexion sign. J Emerg Med. 1989;7(3):287-90.
6. Pinsolle V, Tierny C, Héron A, Reynaud P, Pélissier P. Unfavorable results of reduction
mammoplasty: Causes, preventions and treatments. Ann Chir Plast Esthet. 2019;64(5-6):575-82.
7. Mandrekas AD, Zambacos GJ, Anastasopoulos A, Hapsas DA. Reduction mammaplasty with
the inferior pedicle technique: early and late complications in 371 patients. Br J
Plast Surg. 1996;49(7):442-6.
8. van Deventer PV, Page BJ, Graewe FR. The safety of pedicles in breast reduction and
mastopexy procedures. Aesthetic Plast Surg. 2008;32(2):307-12.
9. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology
of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet.
2020;395(10224):565-74.
10. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression
and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol.
2011;11:37.
11. Lee AM, Wong JG, McAlonan GM, Cheung V, Cheung C, Sham PC, et al. Stress and psychological
distress among SARS survivors 1 year after the outbreak. Can J Psychiatry. 2007;52(4):233-40.
12. Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass:
Post-viral syndrome post COVID-19. Med Hypotheses. 2020;144:110055.
13. Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19
manifestations. Int J Clin Pract. 2021;75(3):e13746.
14. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19
illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327-32.
15. Wilbur J, Shian B. Diagnosis of deep venous thrombosis and pulmonary embolism. Am
Fam Physician. 2012;86(10):913-9.
16. Hatef DA, Kenkel JM, Nguyen MQ, Farkas JP, Abtahi F, Rohrich RJ, et al. Thromboembolic
risk assessment and the efficacy of enoxaparin prophylaxis in excisional body contouring
surgery. Plast Reconstr Surg. 2008;122(1):269-79.
17. ASA and APSF Joint Statement on Elective Surgery and Anesthesia for Patients after
COVID-19 Infection. [Internet]. Schaumburg: American Society of Anesthesiologists.
2020 [acesso 2021 Jan 31]. Disponível em: https://www.asahq.org/about-asa/newsroom/newsreleases/2020/12/asa-and-apsf-joint-statement-on-elective-surgeryand-anesthesia-for-patients-after-covid-19-infection
1. Hospital da Plástica, Cirurgia Plástica e Reconstrutiva, Rio de Janeiro, RJ, Brazil
2. Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
Corresponding author: Thais de Sousa Gonçalves Estrada do Galeão, 2751, sala 212, Rio de Janeiro, RJ, Brazil, Zip Code: 21931-387,
E-mail: thais_sg92@yahoo.com.br
Article received: May 02, 2021.
Article accepted: May 18, 2021.
Conflicts of interest: none.